IntegraGen Presents Data at ESMO 2014 Confirming that its microRNA Biomarker Predicts Survival in Patients with Metastatic Colorectal Cancer.
IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced that it presented data confirming that the oncology biomarker miR-31-3p is predictive of cetuximab effects in all-RAS wild-type
(WT) metastatic colorectal cancer (mCRC) patients during the European Society for Medical Oncology (ESMO) 2014 Congress being held from September 26th to 30th in Madrid, Spain.